Liver Fibrosis-Pipeline Review, H1 2016

Liver Fibrosis-Pipeline Review, H1 2016


  • Products Id :- GMDHC7709IDB
  • |
  • Pages: 193
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Liver Fibrosis-Pipeline Review, H1 2016', provides an overview of the Liver Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Fibrosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Liver Fibrosis

The report reviews pipeline therapeutics for Liver Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Liver Fibrosis therapeutics and enlists all their major and minor projects

The report assesses Liver Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Liver Fibrosis

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Liver Fibrosis Overview 9

Therapeutics Development 10

Pipeline Products for Liver Fibrosis-Overview 10

Pipeline Products for Liver Fibrosis-Comparative Analysis 11

Liver Fibrosis-Therapeutics under Development by Companies 12

Liver Fibrosis-Therapeutics under Investigation by Universities/Institutes 15

Liver Fibrosis-Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Liver Fibrosis-Products under Development by Companies 18

Liver Fibrosis-Products under Investigation by Universities/Institutes 21

Liver Fibrosis-Companies Involved in Therapeutics Development 22

Advinus Therapeutics Ltd. 22

AiCuris GmbH & Co. KG 23

Akarna Therapeutics Ltd. 24

Angion Biomedica Corp. 25

Asubio Pharma Co., Ltd. 26

Bioneer Corporation 27

BiOrion Technologies B.V. 28

Bird Rock Bio, Inc. 29

Bristol-Myers Squibb Company 30

Celgene Corporation 31

Dicerna Pharmaceuticals, Inc. 32

Digna Biotech, S.L. 33

Dr. Falk Pharma GmbH 34

Dynavax Technologies Corporation 35

Evotec AG 36

FibroGen, Inc. 37

Galectin Therapeutics, Inc. 38

Genfit SA 39

Gilead Sciences, Inc. 40

GNI Group Ltd. 41

HEC Pharm Co., Ltd. 42

Immuron Limited 43

Intercept Pharmaceuticals, Inc. 44

INVENT Pharmaceuticals, Inc. 45

Isarna Therapeutics GmbH 46

KineMed, Inc. 47

LG Life Science LTD. 48

Nitto Denko Corporation 49

Pfizer Inc. 50

Pharmaxis Limited 51

Promedior, Inc. 52

Promethera Biosciences S.A. 53

ProMetic Life Sciences Inc. 54

RXi Pharmaceuticals Corporation 55

SciFluor Life Sciences, LLC 56

TCM Biotech International Corp 57

Vascular Biogenics Ltd. 58

Virobay Inc. 59

XTuit Pharmaceuticals, Inc. 60

Liver Fibrosis-Therapeutics Assessment 61

Assessment by Monotherapy Products 61

Assessment by Combination Products 62

Assessment by Target 63

Assessment by Mechanism of Action 66

Assessment by Route of Administration 69

Assessment by Molecule Type 71

Drug Profiles 73

AIC-649-Drug Profile 73

ANG-3070-Drug Profile 74

ANG-3281-Drug Profile 75

ANG-4011-Drug Profile 76

Antisense RNAi Oligonucleotide for Liver Fibrosis-Drug Profile 77

Antisense RNAi Oligonucleotide for Liver Fibrosis-Drug Profile 78

Antisense RNAi Oligonucleotide for Liver Fibrosis-Drug Profile 79

ASB-14780-Drug Profile 80

BMS-986171-Drug Profile 81

BOT-162-Drug Profile 82

CC-539-Drug Profile 83

CIGB-500-Drug Profile 84

CPI-43132-Drug Profile 85

CT-140-Drug Profile 86

DB-036-Drug Profile 87

Drug to Inhibit Galectin-3 for Fibrosis-Drug Profile 88

Drugs for Tissue Fibrosis-Drug Profile 89

DV-1079-Drug Profile 90

F-351-Drug Profile 92

FG-3019-Drug Profile 94

GM-CT-01-Drug Profile 96

GRMD-02-Drug Profile 99

HEC-00000585-Drug Profile 102

HepaStem-Drug Profile 103

IMM-124E-Drug Profile 105

INT-767-Drug Profile 107

INV-340-Drug Profile 109

ISTH-0047-Drug Profile 110

KW-0-Drug Profile 112

LC-280126-Drug Profile 113

melittin-Drug Profile 115

MOR-8457-Drug Profile 116

ND-L02s0201-Drug Profile 117

norursodeoxycholic acid-Drug Profile 119

noscapine-Drug Profile 121

PBI-4050-Drug Profile 122

PRM-151-Drug Profile 124

PXS-5033A-Drug Profile 126

Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Dupuytren Contracture, Peyronies Disease and Transplantation-Drug Profile 127

RXI-209-Drug Profile 128

RYI-018-Drug Profile 129

selonsertib-Drug Profile 130

selonsertib + simtuzumab-Drug Profile 131

Small Molecule for Liver Fibrosis-Drug Profile 132

Small Molecule for Liver Fibrosis-Drug Profile 133

Small Molecule to Agonize FXR for NASH and Liver Fibrosis-Drug Profile 134

Small Molecule to Antagonize AlphaVBetaI for Fibrosis-Drug Profile 135

Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis-Drug Profile 136

Small Molecules for Fibrosis-Drug Profile 137

Small Molecules for Hepatic Fibrosis-Drug Profile 138

Small Molecules for Liver Fibrosis and Idiopathic Pulmonary Fibrosis-Drug Profile 139

Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis-Drug Profile 140

TCM-808FB-Drug Profile 141

TGFTX-4-Drug Profile 142

VB-201-Drug Profile 143

VBY-376-Drug Profile 145

VBY-825-Drug Profile 146

Liver Fibrosis-Recent Pipeline Updates 147

Liver Fibrosis-Dormant Projects 177

Liver Fibrosis-Discontinued Products 180

Liver Fibrosis-Product Development Milestones 181

Featured News & Press Releases 181

Appendix 188

Methodology 188

Coverage 188

Secondary Research 188

Primary Research 188

Expert Panel Validation 188

Contact Us 188

Disclaimer 189

List of Figures

Number of Products under Development for Liver Fibrosis, H1 2016 14

Number of Products under Development for Liver Fibrosis-Comparative Analysis, H1 2016 15

Number of Products under Development by Companies, H1 2016 16

Number of Products under Investigation by Universities/Institutes, H1 2016 19

Comparative Analysis by Clinical Stage Development, H1 2016 20

Comparative Analysis by Early Stage Products, H1 2016 21

Assessment by Monotherapy Products, H1 2016 65

Number of Products by Top 10 Targets, H1 2016 67

Number of Products by Stage and Top 10 Targets, H1 2016 67

Number of Products by Top 10 Mechanism of Actions, H1 2016 70

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 70

Number of Products by Routes of Administration, H1 2016 73

Number of Products by Stage and Routes of Administration, H1 2016 73

Number of Products by Top 10 Molecule Types, H1 2016 75

Number of Products by Stage and Top 10 Molecule Types, H1 2016 75

List of Tables

Number of Products under Development for Liver Fibrosis, H1 2016 14

Number of Products under Development for Liver Fibrosis-Comparative Analysis, H1 2016 15

Number of Products under Development by Companies, H1 2016 16

Number of Products under Development by Companies, H1 2016 (Contd..1) 17

Number of Products under Development by Companies, H1 2016 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H1 2016 19

Comparative Analysis by Clinical Stage Development, H1 2016 20

Comparative Analysis by Early Stage Development, H1 2016 21

Products under Development by Companies, H1 2016 22

Products under Development by Companies, H1 2016 (Contd..1) 23

Products under Development by Companies, H1 2016 (Contd..2) 24

Products under Investigation by Universities/Institutes, H1 2016 25

Liver Fibrosis-Pipeline by Advinus Therapeutics Ltd., H1 2016 26

Liver Fibrosis-Pipeline by AiCuris GmbH & Co. KG, H1 2016 27

Liver Fibrosis-Pipeline by Akarna Therapeutics Ltd., H1 2016 28

Liver Fibrosis-Pipeline by Angion Biomedica Corp., H1 2016 29

Liver Fibrosis-Pipeline by Asubio Pharma Co., Ltd., H1 2016 30

Liver Fibrosis-Pipeline by Bioneer Corporation, H1 2016 31

Liver Fibrosis-Pipeline by BiOrion Technologies B.V., H1 2016 32

Liver Fibrosis-Pipeline by Bird Rock Bio, Inc., H1 2016 33

Liver Fibrosis-Pipeline by Bristol-Myers Squibb Company, H1 2016 34

Liver Fibrosis-Pipeline by Celgene Corporation, H1 2016 35

Liver Fibrosis-Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016 36

Liver Fibrosis-Pipeline by Digna Biotech, S.L., H1 2016 37

Liver Fibrosis-Pipeline by Dr. Falk Pharma GmbH, H1 2016 38

Liver Fibrosis-Pipeline by Dynavax Technologies Corporation, H1 2016 39

Liver Fibrosis-Pipeline by Evotec AG, H1 2016 40

Liver Fibrosis-Pipeline by FibroGen, Inc., H1 2016 41

Liver Fibrosis-Pipeline by Galectin Therapeutics, Inc., H1 2016 42

Liver Fibrosis-Pipeline by Genfit SA, H1 2016 43

Liver Fibrosis-Pipeline by Gilead Sciences, Inc., H1 2016 44

Liver Fibrosis-Pipeline by GNI Group Ltd., H1 2016 45

Liver Fibrosis-Pipeline by HEC Pharm Co., Ltd., H1 2016 46

Liver Fibrosis-Pipeline by Immuron Limited, H1 2016 47

Liver Fibrosis-Pipeline by Intercept Pharmaceuticals, Inc., H1 2016 48

Liver Fibrosis-Pipeline by INVENT Pharmaceuticals, Inc., H1 2016 49

Liver Fibrosis-Pipeline by Isarna Therapeutics GmbH, H1 2016 50

Liver Fibrosis-Pipeline by KineMed, Inc., H1 2016 51

Liver Fibrosis-Pipeline by LG Life Science LTD., H1 2016 52

Liver Fibrosis-Pipeline by Nitto Denko Corporation, H1 2016 53

Liver Fibrosis-Pipeline by Pfizer Inc., H1 2016 54

Liver Fibrosis-Pipeline by Pharmaxis Limited, H1 2016 55

Liver Fibrosis-Pipeline by Promedior, Inc., H1 2016 56

Liver Fibrosis-Pipeline by Promethera Biosciences S.A., H1 2016 57

Liver Fibrosis-Pipeline by ProMetic Life Sciences Inc., H1 2016 58

Liver Fibrosis-Pipeline by RXi Pharmaceuticals Corporation, H1 2016 59

Liver Fibrosis-Pipeline by SciFluor Life Sciences, LLC, H1 2016 60

Liver Fibrosis-Pipeline by TCM Biotech International Corp, H1 2016 61

Liver Fibrosis-Pipeline by Vascular Biogenics Ltd., H1 2016 62

Liver Fibrosis-Pipeline by Virobay Inc., H1 2016 63

Liver Fibrosis-Pipeline by XTuit Pharmaceuticals, Inc., H1 2016 64

Assessment by Monotherapy Products, H1 2016 65

Assessment by Combination Products, H1 2016 66

Number of Products by Stage and Target, H1 2016 68

Number of Products by Stage and Mechanism of Action, H1 2016 71

Number of Products by Stage and Route of Administration, H1 2016 74

Number of Products by Stage and Molecule Type, H1 2016 76

Liver Fibrosis Therapeutics-Recent Pipeline Updates, H1 2016 151

Liver Fibrosis-Dormant Projects, H1 2016 181

Liver Fibrosis-Dormant Projects (Contd..1), H1 2016 182

Liver Fibrosis-Dormant Projects (Contd..2), H1 2016 183

Liver Fibrosis-Discontinued Products, H1 2016 184

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Advinus Therapeutics Ltd. AiCuris GmbH & Co. KG Akarna Therapeutics Ltd. Angion Biomedica Corp. Asubio Pharma Co., Ltd. Bioneer Corporation BiOrion Technologies B.V. Bird Rock Bio, Inc. Bristol-Myers Squibb Company Celgene Corporation Dicerna Pharmaceuticals, Inc. Digna Biotech, S.L. Dr. Falk Pharma GmbH Dynavax Technologies Corporation Evotec AG FibroGen, Inc. Galectin Therapeutics, Inc. Genfit SA Gilead Sciences, Inc. GNI Group Ltd. HEC Pharm Co., Ltd. Immuron Limited Intercept Pharmaceuticals, Inc. INVENT Pharmaceuticals, Inc. Isarna Therapeutics GmbH KineMed, Inc. LG Life Science LTD. Nitto Denko Corporation Pfizer Inc. Pharmaxis Limited Promedior, Inc. Promethera Biosciences S.A. ProMetic Life Sciences Inc. RXi Pharmaceuticals Corporation SciFluor Life Sciences, LLC TCM Biotech International Corp Vascular Biogenics Ltd. Virobay Inc. XTuit Pharmaceuticals, Inc.

Liver Fibrosis Therapeutic Products under Development, Key Players in Liver Fibrosis Therapeutics, Liver Fibrosis Pipeline Overview, Liver Fibrosis Pipeline, Liver Fibrosis Pipeline Assessment

select a license
Single User License
USD 2000 INR 143580
Site License
USD 4000 INR 287160
Corporate User License
USD 6000 INR 430740

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com